No abstract

Menopause is a stage in women's life usually associated with sexual dysfunction. Estrogen plays a significant role in women's sexual well-being. This study aimed to evaluate the effect of Salvia Officinalis extract on the sexual function of postmenopausal women. This was a doubleblind randomized clinical trial on 66 eligible postmenopausal women referring to the Bone Density Measurement Center of Namazi Hospital in Shiraz, Iran in 2015. Subjects in the intervention and control groups daily received three tablets of Salvia Officinalis extract and a placebo, respectively. A sexual function questionnaire with domains of sexual arousal, lubrication, orgasm, and sexual satisfaction was completed for them at the baseline and 3 months after the intervention. Data were analyzed with SPSS-21 software using paired t-test at a significance level of 0.05. The mean score of sexual function, sexual desire, orgasm, sexual satisfaction, and pain relief in the Salvia Officinalis group increased after the intervention by 4.6, 1.1, 0.9, 1.1, and 0.5 units, respectively, which were significantly different from those of the control group. However, the mean score of sexual arousal did not show a statistically significant difference (P= 0.082). Due to the positive effect of Salvia Officinalis on sexual performance scores, it is recommended to be used as a supplement during menopause. Although no significant side effects were observed, further studies are recommended.

No abstract

Background: This study aimed to determine the effect of Salvia officinalis extract and Vitex agnus-castus extract on anxiety in postmenopausal women. Methods: This study was a triple-blind randomized controlled clinical trial on 99 eligible postmenopausal women in Shiraz, Iran. Sampling was done using at the beginning convenience sampling from among women referring to the clinic of Namazi Hospital in Shiraz, Iran, and then permuted block randomization was used to assign patients into three groups in a 1:1:1 ratio, who were divided into 3 groups (2 intervention groups and 1 control group). Data collection tools were a demographic questionnaire and the Spielberger's State-Trait Anxiety Inventory (STAI) questionnaire. The first intervention group received Agnogel tablets (3.2-1.8 mg) once daily, the second group received Salvigol tablets (100 mg) and the third group received placebo (100 mg starch) 3 times a day for 12 weeks. STAI was again completed by the subjects after 3 months.